Clinical utility of polygenic scores for cardiometabolic disease in Arabs

Injeong Shim, Hiroyuki Kuwahara, NingNing Chen, Mais O. Hashem, Lama AlAbdi, Mohamed Abouelhoda, Hong-Hee Won, Pradeep Natarajan, Patrick T. Ellinor, Amit V. Khera, Xin Gao (), Fowzan S. Alkuraya () and Akl C. Fahed ()
Additional contact information
Injeong Shim: Massachusetts General Hospital, Harvard Medical School
Hiroyuki Kuwahara: King Abdullah University of Science and Technology (KAUST)
NingNing Chen: King Abdullah University of Science and Technology (KAUST)
Mais O. Hashem: King Faisal Specialist Hospital and Research Center
Lama AlAbdi: King Faisal Specialist Hospital and Research Center
Mohamed Abouelhoda: King Faisal Specialist Hospital and Research Center
Hong-Hee Won: Sungkyunkwan University, Samsung Medical Center
Pradeep Natarajan: Massachusetts General Hospital, Harvard Medical School
Patrick T. Ellinor: Massachusetts General Hospital, Harvard Medical School
Amit V. Khera: Verve Therapeutics
Xin Gao: King Abdullah University of Science and Technology (KAUST)
Fowzan S. Alkuraya: King Faisal Specialist Hospital and Research Center
Akl C. Fahed: Massachusetts General Hospital, Harvard Medical School

Nature Communications, 2023, vol. 14, issue 1, 1-11

Abstract: Abstract Arabs account for 5% of the world population and have a high burden of cardiometabolic disease, yet clinical utility of polygenic risk prediction in Arabs remains understudied. Among 5399 Arab patients, we optimize polygenic scores for 10 cardiometabolic traits, achieving a performance that is better than published scores and on par with performance in European-ancestry individuals. Odds ratio per standard deviation (OR per SD) for a type 2 diabetes score was 1.83 (95% CI 1.74–1.92), and each SD of body mass index (BMI) score was associated with 1.18 kg/m2 difference in BMI. Polygenic scores associated with disease independent of conventional risk factors, and also associated with disease severity—OR per SD for coronary artery disease (CAD) was 1.78 (95% CI 1.66–1.90) for three-vessel CAD and 1.41 (95% CI 1.29–1.53) for one-vessel CAD. We propose a pragmatic framework leveraging public data as one way to advance equitable clinical implementation of polygenic scores in non-European populations.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-41985-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-41985-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-41985-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().